View More Recent Stories
-
Baird Starts Alumis Inc (ALMS) at Outperform
-
H.C. Wainwright Starts Alumis Inc (ALMS) at Buy
-
Alumis (ALMS) Reports ESK-001 Demonstrated Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
-
Alumis (ALMS) Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
-
Cantor Fitzgerald Starts Alumis Inc (ALMS) at Overweight
-
Morgan Stanley Starts Alumis Inc (ALMS) at Overweight
-
Alumis (ALMS) Opens At $13.50, IPO Priced At $16
-
Alumis (ALMS) Prices 13.125M Share IPO at $16/sh
-
Alumis (ALMS) Announces 17.65M Share IPO at $16-$18/sh
-
Alumis (ALMS) files for proposed IPO
